Scilex Holding Company Announces Issuance Of A Second New Patent In The U.S. For Its Lead Commercial Product ZTlido For A Method Of Relieving Pain Through The Application Of A Non-Aqueous Lidocaine-Containing Patch
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company (NASDAQ: SCLX) has been granted a new U.S. patent (No. 11,786,455) for its lead product ZTlido, a non-aqueous lidocaine patch for pain relief. This patent, along with another recent patent (No. 11,793,766), will be listed in the FDA's Orange Book and extends the intellectual property coverage for ZTlido until 2031, bolstering Scilex's position in non-opioid pain management.
November 17, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scilex Holding Company has been granted a new patent for ZTlido, enhancing its IP portfolio and potentially extending the product's market exclusivity until 2031.
The issuance of a new patent for Scilex's ZTlido product is likely to have a positive impact on the company's stock price in the short term. Patents provide a competitive edge by protecting against generic competition, which can lead to sustained revenue. The fact that this patent extends until 2031 offers a long-term advantage, and its listing in the FDA's Orange Book further solidifies the product's market position. Investors typically view such developments favorably, as they can lead to increased sales and market share.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100